BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33588158)

  • 61. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis.
    Song Z; Yang L; Zhou Z; Li P; Wang W; Cheng G; Chen R; Chang L; Zhang Y; Guan Y; Xia X; Yi X; Zhou R; Chen M
    Cell Death Dis; 2021 Jan; 12(1):106. PubMed ID: 33479213
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells.
    Silva MA; Triltsch N; Leis S; Kanchev I; Tan TH; Van Peel B; Van Kerckhoven M; Deschoolmeester V; Zimmermann J
    J Pathol Clin Res; 2020 Apr; 6(2):124-137. PubMed ID: 31922656
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
    Hwang HS; Kim D; Choi J
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma.
    Steger GG; Gnant MF; Djavanmard MP; Mader RM; Jakesz R; Pierce W; deKernion JB; Figlin R; Belldegrun A
    J Cancer Res Clin Oncol; 1997; 123(6):317-24. PubMed ID: 9222297
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
    Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
    Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland.
    Chen W; Fung AS; McIntyre JB; Simpson R; Afzal AR; Hao D; Lau H
    Clin Invest Med; 2021 Mar; 44(1):E38-41. PubMed ID: 33743575
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tumour immune microenvironment in primary and metastatic papillary renal cell carcinoma.
    Eich ML; Chaux A; Mendoza Rodriguez MA; Guner G; Taheri D; Rodriguez Pena MDC; Sharma R; Allaf ME; Netto GJ
    Histopathology; 2020 Feb; 76(3):423-432. PubMed ID: 31494951
    [TBL] [Abstract][Full Text] [Related]  

  • 69. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
    Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immune inhibitory effects of renal cell carcinoma extract on lectin and alloantigen-induced peripheral blood and tumor infiltrating lymphocyte blastogenesis.
    Shabtai M; Ye H; Kono K; Takayam T; Terashima K; Tsukuda K; Frischer Z; Waltzer WC; Malinowski K
    Urol Oncol; 2003; 21(1):27-32. PubMed ID: 12684124
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response.
    Hajiran A; Chakiryan N; Aydin AM; Zemp L; Nguyen J; Laborde JM; Chahoud J; Spiess PE; Zaman S; Falasiri S; Fournier M; Teer JK; Dhillon J; McCarthy S; Moran-Segura C; Katende EN; Sexton WJ; Koomen JM; Mulé J; Kim Y; Manley B
    Clin Exp Immunol; 2021 Apr; 204(1):96-106. PubMed ID: 33346915
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study.
    Laghi L; Bianchi P; Miranda E; Balladore E; Pacetti V; Grizzi F; Allavena P; Torri V; Repici A; Santoro A; Mantovani A; Roncalli M; Malesci A
    Lancet Oncol; 2009 Sep; 10(9):877-84. PubMed ID: 19656725
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
    Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
    BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
    Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
    Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.
    Wang QJ; Hanada K; Robbins PF; Li YF; Yang JC
    Cancer Res; 2012 Dec; 72(23):6119-29. PubMed ID: 23071066
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
    Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L
    Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
    Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
    Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
    Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
    J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival.
    Pocha K; Mock A; Rapp C; Dettling S; Warta R; Geisenberger C; Jungk C; Martins LR; Grabe N; Reuss D; Debus J; von Deimling A; Abdollahi A; Unterberg A; Herold-Mende CC
    Clin Cancer Res; 2020 May; 26(9):2231-2243. PubMed ID: 31953311
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
    Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
    J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.